medigraphic.com

2018, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2018; 56 (4)

Cost of medical attention in patients with Chronic Obstructive Pulmonary Disease

Villarreal-Ríos E, Julián-Hernández YJ, Vargas-Daza ER, Tapia-Mendoza F, Galicia-Rodríguez L, Martínez-González L

Language: Spanish
References: 19
Page: 371-378
PDF size: 626.69 Kb.


ABSTRACT

Background: The chronic obstructive pulmonary disease is a preventable entity, when it develops the patient suffers severe complications, with a high economic impact for the patient and for health services.
Objective: To determine the cost of medical care in patients with chronic obstructive pulmonary disease (COPD).
Methods: Using a cost design, the files of patients with COPD who attended the pulmonology clinic were analyzed. The size of the sample (n = 265) was calculated with the formula of averages of a finite population. The sample units were captured with the simple random technique. The study variables were: sociodemographic characteristics, characteristics of COPD, annual use profile, unit cost per service, total cost per service and total cost of medical care. The analysis plan included averages, percentages, confidence intervals and health expenditure projections.
Results: the average annual cost of patient care with COPD was $ 89 479.08, of which $ 61 267.63 corresponded to medications. With a COPD prevalence of 25% in a population of 46 million, the calculated cost of care was $ 347 805 183 960.
Conclusions: the cost of medical care in patients with COPD was high, at the expense of medications.


REFERENCES

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report. Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2018. Disponible en: https://goldcopd.org/wpcontent/ uploads/2017/11/GOLD-2018-v6.0-FINAL-revised- 20-Nov_WMS.pdf

  2. Rodríguez JM, De Lucas P, Izquierdo JL, López-Muñiz B, Antón E, Ribera X, et al. Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies. The international Journal Clinical Practice, 2009;63(5):742-750.

  3. Sundeep S. Tobacco Smoking and Environmental Risk Factors for Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2014;35:17-27.

  4. López M, Mongilardi N, Checkley W. Enfermedad pulmonar obstructiva crónica por exposición al humo de biomasa. Rev Peru Med Exp Salud Pública, 2014;31(1):94-99.

  5. Bryant J, McDonald V, Boyes A, Sanson-Fisher R, Melville C. Improving medication adherence in chronic obstructive pulmonary disease: A systematic review. Respiratory Research. 2013;14:109.

  6. Figueroa J, Schiavi E, Mazzei J, López A, Rhodius E, Ciruzzi J, et al. Recomendaciones para la prevención, diagnóstico y tratamiento de la EPOC en la Argentina. Medicina. 2012;72(1):1-33.

  7. Llauger M, Pou M, Domínguez L, Freixas M, Valverde P, Valero C. Atención a la EPOC en el abordaje al paciente crónico en atención primaria. Arch Bronconeumol. 2011;47(11):561-570.

  8. Menezes AM, Perez-Padilla R, Jardim J, Muiño A, López MV, Valdivia G, et al. Chronicobstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet. 2005;366:1875-81.

  9. Moreno A, Montón C, Belmonte Y, Gallego M, Pomares X, Real J. Causas de muerte en pacientes con EPOC grave. Factores pronósticos. Archivos de Bronconeumología. 2009;45(4):181-186.

  10. De la Iglesia F, Serrano J, Montes J. Enfermedad obstructiva crónica (EPOC) y comorbilidades. Galicia Clínica. 2012;73(1): 30-36.

  11. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, ManninoDM, et al. International variation in the prevalence of COPD (The BOLD Study): A population- 2 based prevalence study. Lancet. 2007;370:715-6.

  12. Ancochea J, Badiola C, Duran-Tauleria E, Garcia-Rio F, Miravitlles M, Muñoz L, et al. The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40 to 80 year olds: protocol summary. Arch Bronconeumol. 2009;45(1):41-47.

  13. Guerrero-López CM, Reynales-Shigematsu LM, Jiménez- Ruiz JA, Karam-Araujo R, Maldonado-Cruz CA, Camacho- Solís R. Costos por ausentismo laboral atribuibles al consumo de tabaco en el Instituto Mexicano del Seguro Social y en México, 2006-2009. Salud Pública de México. 2012;54(3):233-241.

  14. Reynales-Shigematsu LM, Juárez-Márquez SA, Valdés- Salgado R. Costos de atención médica atribuibles al tabaquismo en el IMSS, Morelos. Salud Pública de México. 2005;47(6):451-457.

  15. Pérez N, Murillo R, Pinzón C, Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev Colomb Cancerol. 2007;11(4):241-249.

  16. Cano F. Día Mundial de la EPOC. Rev Inst Nal Enf Resp Mex. 2006;19(4):247.

  17. Martínez D, Fernández M, García M, Pérez R. La carga económica de la EPOC. Análisis de los costos a nivel internacional. Neumol Cir Torax. 2011;70(2):118-126.

  18. Reyes GC, Silva OR, Saldías PF. Costo-efectividad de la rehabilitación respiratoria en pacientes con enfermedad pulmonar obstructiva crónica. Rev Chil Enf Respir. 2011;27:153-158.

  19. Diario Oficial de la Federación, (ACUERDO ACDO. AS3.HCT.220217/32.P.DF y sus anexos, dictado por el H. Consejo Técnico, relativo a la aprobación de los Costos Unitarios por Nivel de Atención Médica que regirán para el ejercicio 2017. Disponible en: http://www.dof.gob.mx/nota_detalle.php?codigo=5476988&f echa=21/03/201




2020     |     www.medigraphic.com